VEGFC and neoplasm: Collectively, these findings establish a causative link between the Yap/TAZ-TEAD4-BRD4 complex and VEGF-C activation in promoting tumor lymphangiogenesis and highlight the potential of BET inhibitors as therapeutic agents targeting this pathway.